Home > Legislation > 115th Congress > H.R.1409

H.R.1409 - Cancer Drug Parity Act of 2017115th Congress (2017-2018) |

Bill

Hide Overview
Sponsor: Rep. Lance, Leonard [R-NJ-7] (Introduced 03/07/2017)
Committees: House - Energy and Commerce
Latest Action: House - 03/17/2017 Referred to the Subcommittee on Health.  (All Actions)

Tracker:

This bill has the status Introduced

Here are the steps for Status of Legislation:

  1. Introduced
  2. Passed House
  3. Passed Senate
  4. To President
  5. Became Law

More on This Bill

  • Constitutional Authority Statement
  • CBO Cost Estimates [0]

Subject — Policy Area:

Summary: H.R.1409 — 115th Congress (2017-2018)All Information (Except Text)

There is one summary for H.R.1409. Bill summaries are authored by CRS.

Shown Here:
Introduced in House (03/07/2017)

Cancer Drug Coverage Act of 2017

This bill amends the Public Health Service Act to require group and individual health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medication approved by the Food and Drug Administration that is prescribed based on a finding by the treating physician that the medication is medically necessary for cancer treatment and is clinically appropriate in terms of type, frequency, extent site, and duration.

To comply with this requirement, health plans may not, for anticancer medications: (1) change or replace benefits to increase out-of-pocket costs; (2) reclassify benefits to increase costs; or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.